Get an alert when GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED files next

Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.

Free · confirmation link first · unsubscribe in one click

Next accounts due

2026-09-30 (in 4mo)

Last filed for 2024-12-31

Confirmation statement due

2027-05-04 (in 1y)

Last made up 2026-04-20

Watchouts

None on the register

Cash

Latest balance sheet

Net assets

£1B

+7.6% vs 2023

Employees

3,224

-3.1% vs 2023

Profit before tax

£122M

+6.8% vs 2023

Name history

Renamed 3 times since incorporation

  1. GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED 2001-12-20 → present
  2. GLAXO RESEARCH AND DEVELOPMENT LIMITED 1994-01-01 → 2001-12-20
  3. GLAXO GROUP RESEARCH LIMITED 1978-12-31 → 1994-01-01
  4. MATBURN RESEARCH LIMITED 1965-01-22 → 1978-12-31

Accounts

2-year trend · latest reflected 2024-12-31

Metric Trend 2023-12-312024-12-31
Turnover £1,450,454,000£1,604,456,000
Operating profit £80,447,000£81,021,000
Profit before tax £114,571,000£122,350,000
Net profit £79,988,000£90,350,000
Cash
Total assets less current liabilities £1,206,650,000£1,295,833,000
Net assets £1,190,380,000£1,280,730,000
Equity £1,190,380,000£1,280,730,000
Average employees 3,3283,224
Wages £350,713,000£343,186,000

Values shown as filed in the company's annual accounts. indicates the figure wasn't present under that line item in that period. About these numbers

Ratios

Computed from the line items above — sparklines read oldest → newest

Ratio Trend 2023-12-312024-12-31
Operating margin 5.5%5.0%
Net margin 5.5%5.6%
Return on capital employed 6.7%6.3%
Gearing (liabilities / total assets) 45.4%45.9%
Current ratio 0.67x0.78x
Interest cover 197.66x167.40x

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Audit & accounting basis

Accounting basis
FRS 101
Reporting scope
Standalone (parent only)
Auditor
Deloitte LLP
Audit opinion
Unqualified (clean)
Going concern
Affirmed

“Having assessed the principal risks of the Company and other matters, the Directors are of the opinion that the current level of activity remains sustainable. The Directors in their considerations have included operational risks to research and development including the availability of research facilities and materials. The Directors have considered the Company's ability to continue as a going concern for a minimum of twelve months from the date of signing of these financial statements. The Directors have taken into account that, as part of the Group, the Company has already received the necessary letter of support from GlaxoSmithKline Finance plc and can take actions to ensure business continuity through operational channels, as well as the ability to manage variable costs. On the basis of those considerations, the Directors believe that it remains appropriate to adopt the going concern basis of accounting in preparing the financial statements.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

People

8 active · 30 resigned

Name Role Appointed Born Nationality
WHYTE, Victoria Secretary 2011-02-28 British
GURUNLU RUSS, Demet Director 2024-06-25 Oct 1971 Turkish
KHAVANDI, Kaivan, Dr Director 2024-05-22 Apr 1985 British
LYNCH, Aidan Director 2024-08-20 Feb 1964 Irish
PICKERING, Christopher David George Director 2024-05-22 Mar 1973 British
RIVERS, Graham Paul Director 2023-09-20 May 1971 British
EDINBURGH PHARMACEUTICAL INDUSTRIES LIMITED Corporate Director 2001-01-31
GLAXO GROUP LIMITED Corporate Director 2001-01-31
Show 30 resigned officers
Name Role Appointed Resigned
BICKNELL, Simon Michael Secretary 1998-04-08 2011-02-28
BICKNELL, Simon Michael Secretary 1994-12-08
BOLTON, Jonathan Mark Secretary 1997-08-15 1998-04-08
CHRISTIAN, Christopher Lindsay Secretary 1995-11-01 1997-08-15
HYDE, Jonathan Laurence Patrick Secretary 1994-12-08 1995-10-31
ADAM, Christopher Director 1994-02-16 1995-01-26
ALLEN, David George Director 2015-12-01 2024-04-30
ANDERSON, Jill Dawn Director 2023-03-01 2024-06-25
ANDO, Goran Albert Torstensson, Doctor Director 1995-01-16
ANDRIES, Jerome Charles Maurice Director 2018-04-12 2023-03-01
BAKER, Darrell Director 2010-07-01 2013-02-18
BAXTER, Allan, Dr Director 1995-01-19 2010-06-30
BRITTAIN, Roy Thomas, Dr Director 1992-12-31
BURNS, Alan George Director 2015-09-02 2016-01-29
EAVES, Terence, Doctor Director 1995-07-27 2001-01-31
EAVES, Terence, Doctor Director 1995-01-16
FECZKO, Joseph Michael, Dr Director 1992-11-05 1995-01-30
HALSEY, Audra Jane Director 2021-02-26 2023-09-20
HENNAH, Adrian Director 1995-07-27 1999-03-01
HUMER, Franz Bernhard Director 1994-08-01 1994-12-01
HURT, Douglas Malcolm Director 1993-02-08 1995-07-31
LANCE, Sean Patrick Director 1993-05-24
MARTINDALE, Lucy Gene Director 1999-03-01 2001-01-31
NIEDEL, James Edward, Doctor Director 1995-01-19 2001-03-19
PALMER, James Barry Douglas, Doctor Director 1995-01-19 2002-12-01
PRICE, Barry John, Dr Director 1993-12-01
RICHMOND, Mark Henry, Sir Director 1993-12-01 1995-01-17
ROSS, Barry Clive, Dr Director 1994-02-16 1995-01-30
SYKES, Richard Brook, Sir Director 1994-07-31
TOMLINSON, Ian, Dr Director 2013-02-13 2015-08-01

Ownership

Persons with significant control

Name Kind Nature of control Notified Status
Glaxo Group Limited Corporate entity Shares 75–100%, Voting 75–100%, Appoints directors 2016-04-06 Active

Filing timeline

Last 20 of 239 total filings

Date Type Category Description
2026-04-20 CS01 confirmation-statement Confirmation statement with no updates PDF
2025-08-14 AA accounts Accounts with accounts type full
2025-07-30 CS01 confirmation-statement Confirmation statement with no updates PDF
2024-09-24 CH03 officers Change person secretary company with change date PDF
2024-09-23 CH01 officers Change person director company with change date PDF
2024-09-23 CH01 officers Change person director company with change date PDF
2024-09-20 CH01 officers Change person director company with change date PDF
2024-09-17 CH01 officers Change person director company with change date PDF
2024-09-17 CH01 officers Change person director company with change date PDF
2024-09-17 CH01 officers Change person director company with change date PDF
2024-09-11 AD01 address Change registered office address company with date old address new address PDF
2024-08-29 AP01 officers Appoint person director company with name date PDF
2024-08-15 CS01 confirmation-statement Confirmation statement with no updates PDF
2024-08-14 AA accounts Accounts with accounts type full
2024-07-18 AD02 address Change sail address company with new address PDF
2024-07-12 AP01 officers Appoint person director company with name date PDF
2024-07-05 TM01 officers Termination director company with name termination date PDF
2024-05-23 AP01 officers Appoint person director company with name date PDF
2024-05-23 AP01 officers Appoint person director company with name date PDF
2024-05-10 TM01 officers Termination director company with name termination date PDF

Public-record activity

Raw counts from Companies House — last 12–24 months

Filings
3

last 12 months

Capital events
0

last 24 months

Officers appointed
0

last 12 months

Officers resigned
0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

Year-on-year

FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Official Companies House page